Haleon plc (LON:HLN – Get Free Report)’s share price passed above its fifty day moving average during trading on Monday. The stock has a fifty day moving average of GBX 346.48 and traded as high as GBX 351.60. Haleon shares last traded at GBX 346.70, with a volume of 37,754,125 shares.
Wall Street Analyst Weigh In
Several research analysts have issued reports on HLN shares. Royal Bank Of Canada upped their price target on Haleon from GBX 370 to GBX 390 and gave the company a “sector perform” rating in a report on Tuesday, August 11th. Berenberg Bank reduced their price objective on Haleon from GBX 514 to GBX 365 and set a “buy” rating for the company in a research note on Monday, November 2nd. Deutsche Bank upgraded Haleon to a “hold” rating and decreased their target price for the stock from GBX 320 to GBX 310 in a report on Friday, October 30th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and set a GBX 400 target price on shares of Haleon in a research report on Friday, October 30th. Two equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Haleon currently has a consensus rating of “Hold” and a consensus price target of GBX 356.
View Our Latest Analysis on HLN
Haleon Price Performance
Haleon announced that its board has approved a stock repurchase program on Thursday, October 29th that authorizes the company to repurchase £500 million in shares. This buyback authorization authorizes the company to reacquire up to 1.8% of its shares through open market purchases. Stock buyback programs are generally an indication that the company’s leadership believes its shares are undervalued.
Insider Activity at Haleon
In related news, insider Blathnaid Bergin purchased 7,670 shares of the stock in a transaction dated Friday, October 30th. The shares were acquired at an average cost of GBX 324 per share, for a total transaction of £24,850.80. 0.01% of the stock is currently owned by corporate insiders.
About Haleon
Haleon (LSE / NYSE: HLN) is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges. Haleon’s product portfolio spans six major categories – Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands – such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren – are built on trusted science, innovation and deep human understanding.
Featured Articles
- Five stocks we like better than Haleon
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for Haleon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haleon and related companies with MarketBeat.com's FREE daily email newsletter.
